TSVT 2seventy Bio Company Assets

TSVT (2seventy Bio) - company brandmark

2seventy bio, Inc. (TSVT) is implementing autonomous bioreactors to eliminate manual labor in the production of CAR-T therapies. Currently, the company's R&D portfolio is in a lull following the transfer of programs to a partner, with resources now directed toward software platforms. The total assets market trend on GURU.Markets stands at 492.77. Meanwhile, the business relies on third-party organizations for testing and logistics, focusing its efforts on innovations in cancer therapy.

TSVT - 2seventy bio Company Total Assets over the range 07/04/2022 - 05/24/2025

Analytical breakdowns and data insights for company 2seventy Bio (TSVT)

- share price and expert price forecast:
Price 2seventybio.com|TSVT - Price Target Chart
- market capitalization data:
Market Value 2seventy bio, Inc|TSVT - Total Company Value
- balance sheet equity data:
Equity per Share 2seventy bio|TSVT - Book Capitalization|Market Cap to Net Assets Ratio 2seventybio.com|TSVT - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital 2seventy bio, Inc.|TSVT - Long-Term Debt to Equity|Short-Term Debt to Equity 2seventy bio, Inc|TSVT - Company Debts|Debts to Book Value 2seventy bio, Inc|TSVT - Company Long-Term Debts|Short-Term Indebtedness 2seventy bio|Immediate Liquidity 2seventybio.com
- earnings and market ratios statistics:
TSVT - Net Income
Basic company analysis:TSVT 2seventybio.com
Signature product of 2seventy bio, Inc

The trend in total resources, reverse-calculated via return on assets (ROA), reflects the integration of equity and debt to support operational activities. This metric measures the physical scale of the business, which is critical for 2seventy bio, Inc. (TSVT) when financing costly cell-editing developments for cancer therapy; consequently, a decline in gross assets may signal liquidity shortages and capitalization risks.

Direct competitors

LEGN: Aggregate Business Assets|Aggregate Company Assets Sana Biotechnology, Inc.|Company Assets Autolus Therapeutics PLC AUTL|Aggregate Company Assets Allogene Therapeutics Inc (ALLO)|Selecta Biosciences Inc. - Total Business Assets|Company Total Assets CLLS (Cellectis)|CRBU - Cumulative Company Assets|TIL - Aggregate Company Assets|Company Assets Genenta Science S.p.A.|centurytx.com (IPSC) - Aggregate Company Assets|JSPR (Jasper Therapeutics, Inc.) - Aggregate Company Assets|Aggregate Company Assets Senti Bio|Company Assets Adaptimmune Therapeutics PLC ADAP|Company Total Assets CERO|alaunos.com (TCRT) - Company Balance Sheet Assets|Achilles Therapeutics plc - Cumulative Company Assets|CARGO Therapeutics, Inc (CRGX) - Company Assets|PSTX: Cumulative Company Assets|Aggregate Asset Value GRCL (gracellbio.com)